Plexus Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw 19% year-over-year revenue growth and record new program wins, with strong performance across all sectors. Fiscal 2026 guidance was raised to mid-teens revenue growth and robust margins, supported by operational efficiency and proactive supply chain management.
-
The company is experiencing strong growth momentum, driven by ramping programs in healthcare, industrial, and aerospace/defense sectors. Investments in automation, AI, and global capacity expansion are improving margins and operational efficiency, while proactive supply chain management and a robust balance sheet support continued growth and shareholder returns.
-
The meeting covered board elections, executive compensation, and auditor ratification, all of which passed by majority vote. Fiscal 2025 featured strong financial results, sustainability achievements, and ongoing strategic investments. No shareholder questions were raised.
-
Strong year-over-year revenue and EPS growth were driven by program ramps and market share gains, with robust wins in aerospace/defense and healthcare. Guidance for fiscal 2026 was raised to the high end of the 9%-12% revenue growth target, supported by operational efficiency, automation, and strong end-market demand.
Fiscal Year 2025
-
Fiscal 2025 saw strong revenue, margin, and EPS growth, with robust free cash flow and market share gains. Guidance for fiscal 2026 anticipates revenue growth above end markets, continued margin improvement, and significant investments in automation and capacity.
-
Q3 FY25 delivered sequential revenue growth, 6% non-GAAP operating margin, and strong free cash flow, with robust new program wins and accelerated share repurchases. FY26 outlook anticipates healthy growth across all sectors and sustained profitability.
-
Q2 revenue met guidance at $980M, with non-GAAP EPS of $1.66 exceeding expectations and strong free cash flow. All market sectors showed growth or stabilization, with robust wins and operational efficiency driving margin expansion. Fiscal 2025 outlook remains positive for EPS and free cash flow.
-
The company is focused on complex product markets in healthcare, industrial, and aerospace/defense, achieving strong margins and record free cash flow. Growth is supported by engineering services, global capacity, and operational efficiency, with a flexible approach to tariffs and supply chain shifts.
-
Q1 FY2025 delivered strong results with revenue of $976M and non-GAAP EPS of $1.73, exceeding guidance. Growth is expected across all sectors in FY2025, with semi-cap outpacing the market and robust free cash flow forecasted up to $100M. Commercial aerospace remains a near-term headwind.
Fiscal Year 2024
-
Exceptional Q4 and FY24 results with record free cash flow, margin expansion, and strong program wins. FY25 guidance anticipates robust aerospace and defense growth, moderate gains in healthcare and industrial, and continued operational efficiency.
-
Fiscal Q3 saw strong revenue, margin, and free cash flow, with record program wins and positive customer sentiment. Guidance points to sequential growth and robust margins into Q4 and FY25, supported by sector momentum and operational efficiencies.
-
The company is leveraging its global footprint and focus on complex, regulated markets to drive above-industry growth, with recent improvements in cash flow and operational efficiency. Key sectors like aerospace, healthcare, and semi-cap are showing resilience and recovery, while strategic use of AI and a disciplined approach to M&A support future growth ambitions.